Search
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.
Trofinetide
go.drugbank.com/drugs/DB06045ApprovedTrofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor … [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union.
Synonyms: glycyl-L-2-methylprolyl-L-glutamic acidClozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigationalClozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. … Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.
Products: Aa-clozapine, CLOZAPIN 25 1A PHARMAEtryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's. … In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesFosamprenavir
go.drugbank.com/drugs/DB01319ApprovedInvestigationalFosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Flurpiridaz F-18
go.drugbank.com/drugs/DB18773ApprovedFlurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected … [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659]
Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Carisoprodol
go.drugbank.com/drugs/DB00395Approvedfor abuse in addition to a low risk of dependence [L5074]. … Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications
Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamateMaprotiline
go.drugbank.com/drugs/DB00934ApprovedIt differs from TCAs in that it does not appear to block serotonin reuptake. … Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs).
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigational[L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index